Molecular Partners (MOLN) H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025 summary

Company overview and platform

• Focuses on oncology using a proprietary DARPin platform, enabling targeted therapies with small, modular proteins.

• Pipeline includes radiopharmaceuticals and multispecific DARPins, with programs in phase I and data expected in 2024.

• DARPin technology allows conditional activation and logic-gated immune cell engagement, enhancing specificity and safety.

• Previous licensing deals include anti-VEGF for wet AMD and anti-spike trispecifics, generating significant revenue.

Radiopharmaceuticals and collaborations

• Collaboration with Orano Med centers on lead-212 radiopharmaceuticals, expanded in January 2025 to cover up to 10 products.

• Orano Med provides robust isotope supply and logistics, with centralized manufacturing near a major US distribution hub.

• The partnership structure allows for shared development and commercial rights, with flexibility based on product success.

• Lead-212's short half-life enables daily production and rapid patient treatment, overcoming logistical hurdles.

Pipeline highlights and clinical progress

• DLL3 radiopharmaceutical entering phase I in late 2024, with initial imaging and dosimetry data expected before year-end.

• Mesothelin program targets the membrane-proximal region to avoid competition with shed antigen, improving specificity.

• Logic-gated CD3 Switch-DARPin demonstrated tumor-specific activation and reduced T-cell exhaustion in preclinical studies.

• MP0533 AML program amended dosing to improve response rates, with updated data to be presented at EHA.